Videos

Tags

2020 (21)
AARP (3)
ACA (3)
Active-Pharmaceutical-Ingredients (2)
Addiction (22)
Alzheimer's (3)
Amazon (2)
Anti-bodies (2)
Anti-Competition (3)
Anti-Depressants (2)
Anti-Trust (13)
Anti-Vaccines (9)
Anti-Vaxxers (9)
Antibiotic-Resistance (2)
Antibiotics (9)
Antibodies (4)
Antivirals (2)
API (3)
Artificial-Intelligence (2)
Bacillus-Calmette-Guerin-Vaccine (2)
Bankruptcies (2)
BCG-Vaccine (4)
Bernie-Sanders (14)
Biden (20)
Bill-Gates (4)
Biohackers (5)
Biologics (5)
Biosimilars (8)
Biotechnology (14)
Black-Market (2)
Brexit (5)
Bulk-Buying (5)
Burden-of-Illness (2)
Business-Ethics (14)
Business-Intelligence (28)
Buyers-Club (2)
Cancer (74)
Cancer-Pricing (5)
Cancer-Reimbursement (4)
CAR-T (3)
Carcinogens (2)
CDC (4)
CF (7)
Chemotherapy (4)
Chloroquine (2)
Clinical-Trials (6)
CMS (2)
Co-Insurance (2)
Co-Pays (6)
Code-of-Conduct (21)
Combination-Based-Pricing (2)
Comparative-Effectiveness (7)
Competition (29)
Complex-Generics (2)
Confidence-Levels (3)
Congress (14)
Congressional-Hearing (14)
Copay-Clawback (2)
Coronavirus (212)
Coronavirus-Task-Force (8)
Coronavirus-Testing (12)
Coronavirus-Treatment (199)
Coronavirus-Vaccine (373)
Corporate-Conduct (2)
Cost-Effectiveness (8)
Covax (2)
COVID-19 (360)
COVID-Relief (4)
COVID-Strain (9)
COVID-Variant (3)
Criminal-Investigations (4)
Cross-Border (11)
Cystic-Fibrosis (13)
Daraprim (17)
Depression (3)
Dexamethasone (9)
Diabetes (34)
Disclosure (5)
Distribution-of-Drugs (5)
DNA (2)
DOJ (2)
Drug-Addiction (2)
Drug-Approvals (3)
Drug-Costs (125)
Drug-Coverage (8)
Drug-Development (22)
Drug-Discounts (6)
Drug-Discovery (20)
Drug-Efficacy (3)
Drug-Expenditures (2)
Drug-Importation (20)
Drug-Innovation (22)
Drug-Manufacturing (16)
Drug-Overdose (29)
Drug-Prices (318)
Drug-Pricing (444)
Drug-Rebates (24)
Drug-Recalls (4)
Drug-Resistance (6)
Drug-Shortage (16)
Drug-Spending (2)
Drug-Supply (12)
Drug-Waste (3)
DTC (28)
Ebola (2)
Elections (19)
Emerging-Markets (36)
Epidemics (6)
Epidemiology (6)
EpiPen (13)
EU-Commission (4)
EU-Policy (7)
EU-Politics (4)
Evergreening (3)
Excessive-Pricing (3)
Executive-Order (24)
External-Reference-Pricing (6)
Fair-Price (2)
Favourite-Nations-Clause (2)
FDA (23)
FDA-Approvals (3)
FDA-Warning (3)
fentanyl (13)
Financial-Toxicity (2)
Flu (2)
Formulary-Decision-Making (15)
Fraud (3)
Fraud-Settlements (3)
G7-Countries (2)
Gag-Clauses (2)
Gag-Rules (2)
Gates-Foundation (4)
Gavi-Vaccine-Alliance (5)
Gene-Therapy (14)
Generic-Insulin (2)
Generics (64)
Global-Public-Good (2)
Glybera (2)
H.R._3 (8)
Hacking (4)
HCV (6)
HCV-Pricing (8)
Health-Coverage (4)
Health-Economics (15)
Health-Insurance (4)
Health-Policy (3)
Health-Systems (23)
Health-Technology-Assessment (28)
Healthcare-Costs (15)
Healthcare-Expenditures (10)
Healthcare-Premiums (2)
Healthcare-Pricing (5)
Hepatitis-C (15)
Heroin (4)
HHS (15)
HIV (2)
HIV-AIDS (15)
HIV-Pricing (5)
Hospital-Pricing (7)
Hospitalizations (3)
Hospitals (6)
House-Hearing (6)
HTA (9)
Hydroxychloroquine (10)
ICER (9)
Illegal-Drugs (2)
Immunotherapy (2)
Indicated-Based-Pricing (2)
Infectious-Diseases (11)
Innovation (4)
Insulin (115)
Insulin-Bills (5)
Insulin-Pricing (61)
Insulin-Rationing (36)
Insurance-Caps (2)
International-Comparisons (13)
International-Pricing-Index (5)
International-Pricing-Referencing (12)
Investments (10)
Investor-Relations (3)
Kick-Backs (10)
Know-the-Lowest-Price-Act (11)
Launch-Pricing (5)
Lawsuit-Settlements (15)
Lawsuits-Litigations (55)
List-Prices (20)
Lobbying (6)
Lupus (3)
Malaria (7)
Mandatory-Cuts (5)
Marijuana (2)
Market-Access (40)
Market-Exclusivity (5)
Market-Intelligence (30)
McKinsey (2)
Measles (2)
Mediator (2)
Medicaid (4)
Medical-Devices (5)
Medical-Ethics (6)
Medical-History (4)
Medical-Implants (5)
Medical-Innovation (2)
Medical-Marketing (7)
Medical-Supplies (2)
Medicare (20)
Medicare-for-all (13)
Medicare-Negotiations (9)
Mental-Ilness (5)
Mergers-Acqusitions (6)
Midterms (6)
Migraine (3)
Monoclonal-Antibodies (2)
Most-Favoured-Nation (7)
mRNA-Vaccines (2)
MS (2)
MSF (2)
Multiple-Sclerosis (3)
NAFTA (8)
Naloxone (4)
National-Pharmacare (13)
National-Strategy (2)
Neglected-Diseases (2)
Net-Prices (2)
Netflix-Model (7)
NHS (31)
NICE (19)
NIH (2)
Obamacare (9)
OECD (2)
Off-Label (5)
Off-Patent (3)
Opioids (161)
Orkambi (4)
Orphan-Drugs (20)
Out-of-Pocket (7)
OxyContin (29)
Pain-killers (2)
Pandemics (9)
Panic-Buying (3)
Parallel-Trade (2)
Patent-Protection (19)
Patent-System-Reform (2)
Patents (11)
Patient-Access (178)
Patient-Advocacy (4)
Patient-Affordability (23)
Patient-Costs (4)
patient-outcomes (5)
Patient-Safety (13)
Patients-Right-to-Know-Drug-Prices-Act (2)
Pay-for-Delay (4)
Pay-For-Performance (5)
Payments (2)
PBM-Pricing (2)
PBMs (28)
PBS (3)
Pediatric-Cancers (2)
Penalties-Fines (4)
Personal-Importation (20)
Pharma-Bro (4)
Pharma-Influence (10)
Pharmaceutical-Middlemen (2)
Pharmaceuticals (6)
Pharmacists (4)
Pharmacoeconomics (4)
Pharmacy-Benefits-Managers (43)
Pharmacy-Chains (2)
PMPRB (9)
Policy (3)
Polio (3)
Precision-Medicine (2)
Presidential-Race (11)
Price-Caps (4)
Price-Controls (17)
Price-Cuts (9)
Price-Fixing (10)
Price-gouging (30)
Price-Hikes (92)
Price-Increases (44)
Price-Inflation (4)
Price-Negotiations (13)
Price-Regulations (22)
Price-Transparency (30)
Pricing-Bills (29)
Pricing-Blueprint (24)
Pricing-Board (3)
Pricing-Caps (10)
Pricing-Complaints (2)
Pricing-Legislation (49)
Pricing-Models (2)
Pricing-Negotiations (3)
Pricing-Reform (10)
Pricing_Collusion (9)
Prior-Approvals (2)
Prior-Authorization (3)
Procurement-Lists (2)
Production-Logistics (13)
Productivity (2)
Profiteering (3)
Profits-Revenues (3)
Provincial-Access (3)
Public-Funding (5)
Public-Health (47)
Public-Opinion (12)
Public-Policy (4)
Public-Trust (11)
Purdue-Pharma (40)
QALYs (2)
Quality-Control (2)
R&D (14)
Rare-Diseases (26)
Real-World-Data (4)
Real-World-Evidence (6)
Reference-Pricing (9)
Regulatory-Affairs (4)
Reimbursement (7)
Reimportation (5)
Relief-Bill (3)
Remdesivir (37)
Repurposing (2)
Respiratory-Disease (3)
Right-to-Try (3)
Risk-Sharing-Agreements (2)
RWD (2)
RWE (2)
Sackler-Family (28)
Safe-Importation (2)
Safety-Standards (9)
Senate-Hearings (20)
Shkreli (11)
Sickle-Cell-Disease (2)
Side-Effects (2)
Single-Payer (21)
x Skin-Care (1)
SMA (3)
Smoking (2)
SOTU (5)
Sovaldi (3)
Specialty-Drugs (4)
Spinal-Muscular-Atrophy (7)
Spinraza (4)
State-level (110)
Step-Therapy (3)
Stock-Market (2)
Supply-Chain (9)
Tariffs (3)
Tax-Credits (3)
TB (4)
Thalidomide (3)
Theranos (2)
Top-10 (2)
Trade (22)
Treatment-Cost (3)
TRIPS (2)
Trump (227)
Trump (379 (3)
Tuberculosis (3)
TV-Ads (30)
UK-Politics (6)
Uninsured (2)
Universal-Healthcare (20)
US-Insurers (59)
US-Policy (59)
US-Politics (154)
USMCA (9)
Vaccinations (35)
Vaccine-Access (11)
Vaccine-Deal (5)
Vaccine-Development (2)
Vaccine-Diplomacy (11)
Vaccine-Distribution (37)
Vaccine-Efficacy (3)
Vaccine-Nationalism (7)
Vaccine-Passport (3)
Vaccine-Pricing (11)
Vaccine-Programs (2)
Vaccine-Rollout (30)
Vaccine-Supply (21)
Vaccines (274)
Value-Based-Medicine (2)
Value-based Contracts (6)
Value-based Payment (12)
Value-based Pricing (32)
Value-in-Health (9)
Value-of-Medicines (3)
Vaping (2)
Vincristine (5)
Viral-Mutations (7)
Viral-Strain (9)
Wall-St (4)
Wealth-Distribution (2)
Whistleblowers (2)
WHO (13)
Zantac (3)
Zolgensma (6)

Reset All Filters
1 result found
x Skin-Care

Bookmark this

Pharmaceutical Giants Rebrand Skin-Whitening Products in Asia

Unilever and Johnson & Johnson have agreed to either discontinue or rebrand its skin-whitening products sold across Asia following a backlash over how they're marketed.

@ABCaustralia Jun 26, 2020

Like

Like
0

Comments

No comments yet. Create an account and log in to post a comment.

Date Published

Country

Source

Tags

Videos

Pharmaceutical Giants Rebrand Skin-Whitening Products in Asia

Comments

Subscribe by email